Chlamydia trachomatis causes common infections of the eyes and genital tract in man. The mechanism by which this obligate intracellular bacterium is taken into epithelial cells is unclear. The results described here support the concept that chlamydial infection of HeLa cells is under bidirectional cyclic nucleotide control, with guanosine 3′:5′-cyclic monophosphate (cGMP) acting as a stimulator, and adenosine 3′:5′-cyclic monophosphate (cAMP) as an inhibitor. Treatment of the HeLa cells with the divalent cation ionophore A23187, with carbamoylcholine, or with prostaglandins known to increase the concentration of endogenous cGMP, also increased host cell susceptibility to chlamydial infection. Cyclic GMP was only effective if added at or before chlamydial inoculation, suggesting that its main effect was on chlamydial uptake. The stimulatory effect of cGMP, but not antagonism by cAMP, was abolished if the cells were first treated with any of four different inhibitors of prostaglandin synthesis, suggesting a critical role for endogenous prostaglandin synthesis. Centrifugation of chlamydiae on to host cells was followed by a rapid increase in the mobility of Ca2+ across the cell membrane. The interrelationships of these observations and the possibility that chlamydiae and other intracellular pathogens might evoke alterations in host cell prostaglandin and cyclic nucleotide concentrations to aid their own uptake are discussed.
ByrneG. I., MoulderJ. W.1978; Parasite-specified phagocytosis of Chlamydia psittaci and Chlamydia trachomatis by L and HeLa cells. Infection and Immunity 19:598–606
CoxJ. P., KarnovskyM. L.1973; The depression of phagocytosis and exogenous cyclic nucleotides, prostaglandins and theophylline. Journal of Cell Biology 59:480–490
GoldbergN. D., HaddoxM. K., DunhamI., LopezC., HaddenJ. W.1974; The Ying Yang hypothesis of biological control: opposing influences of cyclic GMP and cyclic AMP in the regulation of cell proliferation and other biological processes. In Control of Proliferation in Animal Cells pp. 609–625ClarksonB., BasergaR. Edited by Cold Spring Harbor Laboratory:
GoldbergN. D., GraffG., HaddoxM. K., StephensonJ. H., GlassD. B., MoserM. E.1978; Redox modulation of splenic soluble guanylate cyclase activity: activation by hydrophilic oxidants represented by ascorbic and dehydroascorbic acids, fatty acid hydroperoxides, and prostaglandin endoperoxides. Advances in Cyclic Nucleotide Research 9:101–158
GriffinF. M.JrGriffinJ. A., LeiderJ., SilversteinS. C.1975; Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane. Journal of Experimental Medicine 142:1263–1282
KankelE., HilzH.1972; Permeation of dibutyryl cAMP into HeLa cells and its conversion to monobutyryl cAMP. Biochemical and Biophysical Research Communications 46:1011–1018
MalmstenC., GranstromE., SamuelssonB.1976; Cyclic AMP inhibits synthesis of prostaglandin endoperoxide (PGG2) in human platelets. Biochemical and Biophysical Research Communications 68:569–576
MinkesM., StanfordN., ChiM.M-Y., RothG. J., RazA., NeedlemanP., MajerusP. W.1977; Cyclic adenosine 3´,5´-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions. Journal of Clinical Investigation 59:449–454
RussellW. C., NewmanC., WilliamsonD. H.1975; A simple cytochemical technique for demonstration of DNA in cells infected with mycoplasma and viruses. Nature; London: 253461–462
StirlingP., RichmondS.1977; The developmental cycle of Chlamydia trachomatis in McCoy cells treated with cytochalasin. Journal of General Microbiology 100:31–42
WardM. E., SalariS. H.1980; Modulation of Chlamydia trachomatis infection by cyclic nucleotides and prostaglandins. FEMS Microbiology Letters 7:141–143
ZurierR. B., WeissmannG., HoffsteinS., KammermanS., TaiH. H.1974; Mechanisms of lysosomal enzyme release from human polymorphs. II. Effects of cAMP, cGMP, autonomic antagonists and agents which affect microtubule function. Journal of Clinical Investigation 53:297–309